REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial

The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel -methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episod...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The American journal of psychiatry 2022-02, Vol.179 (2), p.122-131
Hauptverfasser:	Fava, Maurizio, Stahl, Stephen, Pani, Luca, De Martin, Sara, Pappagallo, Marco, Guidetti, Clotilde, Alimonti, Andrea, Bettini, Ezio, Mangano, Richard M, Wessel, Thomas, de Somer, Marc, Caron, Judy, Vitolo, Ottavio V, DiGuglielmo, Gina R, Gilbert, Adam, Mehta, Hiren, Kearney, Morgan, Mattarei, Andrea, Gentilucci, Marco, Folli, Franco, Traversa, Sergio, Inturrisi, Charles E, Manfredi, Paolo L
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidepressants Antidepressive Agents - adverse effects Clinical trials Depressive Disorder, Major - diagnosis Depressive Disorder, Major - drug therapy Double-Blind Method Double-blind studies Humans Medical treatment Mental depression Pharmacokinetics Placebo effect Side effects Suicidal Ideation Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!